澄清精密醫學

2023年6月1日

與關注病人和社區腫瘤學家,合作夥伴將更多的分子VieCure測試結果為可行的治療,癌症護理公司領先的人工智能,信息,和臨床決策支持平台,宣布了一項新的戰略合作澄清精密醫學這將使精密的腫瘤更容易讓病人和社區腫瘤學家。近年來已經有一個大轉向使用特定的癌症治療方案,特別是應對癌症的分子概要文件(例如,基因組數據)。相當大,這些數據點是複雜和困難的訪問在社區腫瘤級別腫瘤部分基於更改/更新響應數據。這突顯出一個至關重要的醫學指導供應商和類股和動機VieCure和澄清精密醫學共同努力為腫瘤專家和他們的病人提供清晰,可用任何商業全麵解釋分子分析測試以及治療方案的排名列表由國家認可的精度了腫瘤學專家。這一夥伴關係也將促進目標,第三方臨床評估協助與之前付款人授權或審批決策作為決策過程的一部分,臨床醫生。“我們正在興奮中嵌入我們的專長,進一步加快采用精密腫瘤學和幫助更多的患者和提供者未來幾年“VieCure將充分整合澄清精密醫學體細胞和生殖係臨床谘詢過程中人工智能平台和提供社區腫瘤學家流線型澄清的全國公認的測試解釋團隊。這些專業人士將函數作為彈性/按需供應臨床供應商每天在地上不知疲倦地工作來幫助癌症患者,為他們提供最好的特定的選項。澄清精密醫學還開發了額外的工具,幫助供應商管理毒性,整體優化支持性護理,提高臨床工作效率。VieCure-Clarified夥伴關係提供了一個精確腫瘤學專家考慮,地方精英,精密醫學專家可以在使用VieCure訪問指導臨床決策支持平台。“我們正在興奮中嵌入我們的專長,進一步加快采用精密腫瘤學和幫助更多的患者和提供者未來幾年,”博士說霍華德•麥克勞德眾人認同精密腫瘤學專家。 VieCure will integrate the Clarified Medicine Precision testing tools within its platform and make the Clarified offering available to oncologists and clinical users later this year. Oncologists using the VieCure platform will be able to order their molecular test (e.g., next generation tumor sequencing) directly out of the VieCure platform and then obtain their precision medicine review within 48 hours following three easy steps: VieCure’s platform ingests discrete molecular test results for review and interpretation. Clarified Precision Medicine’s clinical experts will review the molecular test results. Upon receipt of the molecular test results, the clinical provider will receive an easy-to-understand report condensing the patient’s results into a ranked list of treatment options (including clinical trials) and suggestions about any additional testing, if necessary, directly within the VieCure platform. Furthermore, the provider also has the ability to connect with the Clarified Precision Medicine expert to discuss the results as needed. VieCure will launch a pilot program at Alabama Cancer Care, granting early access to the ClarifiedSelect Report embedded in the VieCure platform. This is a tremendous step to improve access to next-generation cancer care for all and help ensure cancer patients live their best lives. “VieCure and Clarified Precision Medicine, together, are further democratizing precision oncology and making it easier for community oncologists to offer the right care for the right patient every time,” said Dr. Fred Ashbury , Chief Scientific Officer at VieCure.